← Leaderboards
Jane Amanda Skok
New York University School Of Medicine
$18,379,753
Attributed
$20,994,729
Total exposure
14
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,473,227 · 15
By mechanism
P01$15,776,532 · 5
R01$8,573,014 · 4
R35$6,320,186 · 1
RC1$999,998 · 1
R21$858,188 · 2
R56$814,999 · 1
Top collaborators
- Yuval Kluger7 shared
- Benjamin G. Neel4 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Aristotelis Tsirigos$7,163,614
- Benjamin G. Neel$33,134,772
- Sandra Demaria$8,493,423
- Yuval Kluger$14,295,762
- Adriana Heguy$4,473,548
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesChromatinChromosomesPlayArchitectureMediatingGenetic TranscriptionGenomeGene Expression RegulationCellsMalignant NeoplasmsPhenotypeProgramsInsightLinkProteinsEpigenetic ProcessNuclearEnhancersComplexGenetic RecombinationAllelesRegulationCohesin
Grant awards (58)
The impact of changes in chromatin architecture on cancer phenotypes and tumor progression$2,304,725
P01 · FY2025 · CA · contact PI
Nuclear organization and its role in gene regulation$742,410
R35 · FY2025 · GM · contact PI
Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1$703,389
R01 · FY2025 · CA · contact PI
The biochemical, topological and functional impact of cancer-associated Ctcfmutations and their contribution to cancer$432,414
P01 · FY2025 · CA · contact PI
Administrative Core$145,227
P01 · FY2025 · CA · contact PI
Nuclear organization and its role in gene regulation$742,410
R35 · FY2024 · GM · contact PI
Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1$668,222
R01 · FY2024 · CA · contact PI
The impact of changes in chromatin architecture on cancer phenotypes and tumor progression$1,984,949
P01 · FY2023 · CA · contact PI
Nuclear organization and its role in gene regulation$742,410
R35 · FY2023 · GM · contact PI
Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1$689,321
R01 · FY2023 · CA · contact PI
Project 1: The biochemical, topological and functional impact of cancer associated Ctcfmutations and their contribution to cancer$403,384
P01 · FY2023 · CA · contact PI
Administrative Core$138,874
P01 · FY2023 · CA · contact PI
The impact of changes in chromatin architecture on cancer phenotypes and tumor progression$1,984,949
P01 · FY2022 · CA · contact PI
Nuclear organization and its role in gene regulation$742,410
R35 · FY2022 · GM · contact PI
Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1$702,264
R01 · FY2022 · CA · contact PI
Project 1: The biochemical, topological and functional impact of cancer associated Ctcfmutations and their contribution to cancer$319,441
P01 · FY2022 · CA · contact PI
Administrative Core$160,206
P01 · FY2022 · CA · contact PI
Cancer Genome Dynamics (CGD) Research Program$32,775
P30 · FY2022 · CA · contact PI
The impact of changes in chromatin architecture on cancer phenotypes and tumor progression$2,107,225
P01 · FY2021 · CA · contact PI
Mechanisms Underlying the Control of Recombination and Gene Regulation$713,367
R35 · FY2021 · GM · contact PI
Project 1: The biochemical, topological and functional impact of cancer associated Ctcfmutations and their contribution to cancer$414,691
P01 · FY2021 · CA · contact PI
Administrative Core$166,167
P01 · FY2021 · CA · contact PI
Cancer Genome Dynamics (CGD) Research Program$32,775
P30 · FY2021 · CA · contact PI
The impact of changes in chromatin architecture on cancer phenotypes and tumor progression$2,030,950
P01 · FY2020 · CA · contact PI
Mechanisms Underlying the Control of Recombination and Gene Regulation$713,531
R35 · FY2020 · GM · contact PI
Project 1: The biochemical, topological and functional impact of cancer associated Ctcfmutations and their contribution to cancer$417,106
P01 · FY2020 · CA · contact PI
Administrative Core$141,709
P01 · FY2020 · CA · contact PI
Cancer Genome Dynamics (CGD) Research Program$32,500
P30 · FY2020 · CA · contact PI
The impact of changes in chromatin architecture on cancer phenotypes and tumor progression$2,065,700
P01 · FY2019 · CA · contact PI
Mechanisms Underlying the Control of Recombination and Gene Regulation$713,714
R35 · FY2019 · GM · contact PI
Project 1: The biochemical, topological and functional impact of cancer associated Ctcfmutations and their contribution to cancer$417,106
P01 · FY2019 · CA · contact PI
Administrative Core$141,709
P01 · FY2019 · CA · contact PI
Cancer Genome Dynamics (CGD) Research Program$32,260
P30 · FY2019 · CA · contact PI
Mechanisms Underlying the Control of Recombination and Gene Regulation$713,885
R35 · FY2018 · GM · contact PI
The biochemical, topological and functional impact of cancer associated Ctcf mutations and their contribution to cancer$481,945
R01 · FY2018 · CA · contact PI
Mechanisms Underlying the Control of Recombination and Gene Regulation$496,049
R35 · FY2017 · GM · contact PI
Enhancer Driven Gene Regulation During Lymphocyte Development$525,166
R01 · FY2016 · GM · contact PI
Role Of Nuclear Organization In Protecting Genome Stability During Recombination$387,408
R01 · FY2016 · GM · contact PI
Translocations And Their Widespread Impact on Gene Regulation$183,950
R21 · FY2016 · CA · contact PI
Enhancer Driven Gene Regulation During Lymphocyte Development$525,166
R01 · FY2015 · GM · contact PI
Role Of Nuclear Organization In Protecting Genome Stability During Recombination$387,408
R01 · FY2015 · GM · contact PI
Translocations And Their Widespread Impact on Gene Regulation$220,825
R21 · FY2015 · CA · contact PI
Enhancer Driven Gene Regulation During Lymphocyte Development$525,166
R01 · FY2014 · GM · contact PI
Role Of Nuclear Organization In Protecting Genome Stability During Recombination$387,408
R01 · FY2014 · GM · contact PI
The Role of RNA in Regulating recombination and allelic exclusion$254,250
R21 · FY2014 · AI · contact PI
Co-ordination of recombination and allelic exclusion at IgH and Igk loci$84,750
R01 · FY2014 · GM · contact PI
Role Of Nuclear Organization In Protecting Genome Stability During Recombination$404,783
R01 · FY2013 · GM · contact PI
Role of ATM and RAG in maintaining genome stability during Tcra/d rearrangement.$392,500
R56 · FY2013 · AI · contact PI
The Role of RNA in Regulating recombination and allelic exclusion$199,163
R21 · FY2013 · AI · contact PI
Role of ATM and RAG in maintaining genome stability during Tcra/d rearrangement.$422,499
R56 · FY2012 · AI · contact PI
Co-ordination of recombination and allelic exclusion at IgH and Igk loci$332,254
R01 · FY2012 · GM · contact PI
Co-ordination of recombination and allelic exclusion at IgH and Igk loci$332,254
R01 · FY2011 · GM · contact PI
Spatiotemporal control of recombination by the RAG proteins and ATM$500,000
RC1 · FY2010 · CA · contact PI
Co-ordination of recombination and allelic exclusion at IgH and Igk loci$335,610
R01 · FY2010 · GM · contact PI
Spatiotemporal control of recombination by the RAG proteins and ATM$499,998
RC1 · FY2009 · CA · contact PI
Co-ordination of recombination and allelic exclusion at IgH and Igk loci$422,500
R01 · FY2009 · GM · contact PI
Co-ordination of recombination and allelic exclusion at IgH and Igk loci$339,000
R01 · FY2009 · GM · contact PI
Co-ordination of recombination and allelic exclusion at IgH and Igk loci$339,000
R01 · FY2008 · GM · contact PI